Cargando…

P808: CONTROLLED FRATRICIDE TO AUGMENT ANTI-MYELOMA REACTIVITY OF SLAMF7 AND CD38 CAR T CELLS

Detalles Bibliográficos
Autores principales:	Konetzki, Verena, Heyer, Kersten, Einsele, Hermann, Hudecek, Michael, Prommersberger, Sabrina
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430616/ http://dx.doi.org/10.1097/01.HS9.0000970136.35823.f7

Ejemplares similares

CARAMBA: a first-in-human clinical trial with SLAMF7 CAR-T cells prepared by virus-free Sleeping Beauty gene transfer to treat multiple myeloma
por: Prommersberger, Sabrina, et al.
Publicado: (2021)

Treatment of multiple myeloma with the immunostimulatory SLAMF7 antibody elotuzumab
por: Einsele, Hermann, et al.
Publicado: (2016)

P836: ANTIBODY-DRUG CONJUGATES AS POTENTIAL CAR-T CELL SPECIFIC OFF-SWITCH IN MULTIPLE MYELOMA
por: Bielowski, Anna, et al.
Publicado: (2023)

CS1 CAR-T targeting the distal domain of CS1 (SLAMF7) shows efficacy in high tumor burden myeloma model despite fratricide of CD8+CS1 expressing CAR-T cells
por: O’Neal, Julie, et al.
Publicado: (2022)

Elotuzumab for the treatment of extramedullary myeloma: a retrospective analysis of clinical efficacy and SLAMF7 expression patterns
por: Danhof, Sophia, et al.
Publicado: (2021)

All-trans retinoic acid works synergistically with the γ-secretase inhibitor crenigacestat to augment BCMA on multiple myeloma and the efficacy of BCMA-CAR T cells
por: García-Guerrero, Estefanía, et al.
Publicado: (2022)

CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
por: Radhakrishnan, Sabarinath V., et al.
Publicado: (2020)

CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
por: Rodríguez-Lobato, Luis Gerardo, et al.
Publicado: (2020)

An ‘off-the-shelf’ fratricide-resistant CAR-T for the treatment of T cell hematologic malignancies
por: Cooper, Matthew L., et al.
Publicado: (2018)

Trogocytosis and fratricide killing impede MSLN-directed CAR T cell functionality
por: Schoutrop, Esther, et al.
Publicado: (2022)

Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2020)

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T
por: Nerreter, Thomas, et al.
Publicado: (2019)

Publisher Correction: Upregulation of CD38 expression on multiple myeloma cells by novel HDAC6 inhibitors is a class effect and augments the efficacy of daratumumab
por: García-Guerrero, Estefanía, et al.
Publicado: (2021)

SLAMF6 clustering is required to augment T cell activation
por: Dragovich, Matthew A., et al.
Publicado: (2019)

A descriptive study of fratricide in tunisia
por: Guermazi, A., et al.
Publicado: (2021)

Clinical impact of serum soluble SLAMF7 in multiple myeloma
por: Ishibashi, Mariko, et al.
Publicado: (2018)

Inhibition of TGF-β-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer
por: Stüber, Tanja, et al.
Publicado: (2020)

Negative Regulation of Humoral Immunity Due to Interplay between the SLAMF1, SLAMF5, and SLAMF6 Receptors
por: Wang, Ninghai, et al.
Publicado: (2015)

Overcoming Target Driven Fratricide for T Cell Therapy
por: Breman, Eytan, et al.
Publicado: (2018)

Clinical potential of SLAMF7 antibodies – focus on elotuzumab in multiple myeloma
por: Friend, Reed, et al.
Publicado: (2017)

SLAMF7 as a Promising Immunotherapeutic Target in Multiple Myeloma Treatments
por: Chu, Emily, et al.
Publicado: (2023)

CRISPR-Mediated Triple Knockout of SLAMF1, SLAMF5 and SLAMF6 Supports Positive Signaling Roles in NKT Cell Development
por: Huang, Bonnie, et al.
Publicado: (2016)

Activation of plasmacytoid dendritic cells promotes AML-cell fratricide
por: Fatehchand, Kavin, et al.
Publicado: (2021)

Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
por: Zhou, Xiang, et al.
Publicado: (2020)

European Myeloma Network perspective on CAR T-cell therapies for multiple myeloma
por: Bruno, Benedetto, et al.
Publicado: (2021)

NK-cell fratricide: Dynamic crosstalk between NK and cancer cells
por: Nakamura, Kyohei, et al.
Publicado: (2013)

CrfP, a fratricide protein, contributes to natural transformation in Streptococcussuis
por: Zhu, Yinchu, et al.
Publicado: (2021)

Automated, scaled, transposon-based production of CAR T cells
por: Lock, Dominik, et al.
Publicado: (2022)

Responses to Microbial Challenges by SLAMF Receptors
por: van Driel, Boaz Job, et al.
Publicado: (2016)

Migration of Myeloid Cells during Inflammation Is Differentially Regulated by the Cell Surface Receptors Slamf1 and Slamf8
por: Wang, Guoxing, et al.
Publicado: (2015)

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma
por: Campbell, Kerry S., et al.
Publicado: (2018)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma
por: Li, Hongwen, et al.
Publicado: (2023)

CRISPR-Mediated Slamf1(Δ/Δ) Slamf5(Δ/Δ) Slamf6(Δ/Δ) Triple Gene Disruption Reveals NKT Cell Defects but Not T Follicular Helper Cell Defects
por: Hu, Joyce K., et al.
Publicado: (2016)

Elotuzumab for the Treatment of Relapsed or Refractory Multiple Myeloma, with Special Reference to its Modes of Action and SLAMF7 Signaling
por: Taniwaki, Masafumi, et al.
Publicado: (2018)

SLAMF6 compartmentalization enhances T cell functions
por: Gartshteyn, Yevgeniya, et al.
Publicado: (2022)

Siplizumab Induces NK Cell Fratricide Through Antibody-Dependent Cell-Mediated Cytotoxicity
por: Binder, Christian, et al.
Publicado: (2021)

SLAMF6 deficiency augments tumor killing and skews toward an effector phenotype revealing it as a novel T cell checkpoint
por: Hajaj, Emma, et al.
Publicado: (2020)

Patient selection for CAR T or BiTE therapy in multiple myeloma: Which treatment for each patient?
por: Kegyes, David, et al.
Publicado: (2022)

TRAIL Dependent Fratricidal Killing of gp120 Primed Hepatocytes by HCV Core Expressing Hepatocytes
por: Rizza, Stacey A., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_l36aq5t0580si25cjt2immc88m